BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior
暂无分享,去创建一个
[1] J. Swensen,et al. Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.
[2] C. Fletcher,et al. Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.
[3] M. Ladanyi,et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.
[4] B. Taylor,et al. Abstract LB-302: Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma , 2017 .
[5] R. Shoemaker,et al. Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing , 2016, Applied immunohistochemistry & molecular morphology : AIMM.
[6] Roland Eils,et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.
[7] C. Sarkar,et al. Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma , 2003, Journal of Biosciences.
[8] S. O’Rahilly,et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay , 2004, Nature Neuroscience.
[9] P. S. Kim,et al. Structure of the Bcr-Abl oncoprotein oligomerization domain , 2002, Nature Structural Biology.
[10] W. Hamel,et al. Trk A, B, and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma , 1998, Acta Neuropathologica.
[11] J. Trojanowski,et al. Expression of trk receptors in the developing and adult human central and peripheral nervous system , 1995, The Journal of comparative neurology.